一个数据驱动的认知复合材料,对阿米洛伊德β敏感,用于临床前阿尔茨海默病
Shu Liu1,2, Paul Maruff2,3, Victor Fedyashov1,2
1ARC Training Centre in Cognitive Computing for Medical Technologies, University of Melbourne, Carlton, VIC, Australia.
Journal of Alzheimer's disease : JAD
|September 13, 2024
概括
一种新的数据驱动的认知复合物,D-PACC,在认知不受损的个体中显示出更好的灵敏度来检测粉样β (Aβ) 状态. 这种新的复合材料可以在不同研究中更一致地检测临床前阿尔茨海默病生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 认知评估 认知评估
背景情况:
- 认知复合材料增强了与阿尔茨海默病 (AD) 相关的损伤的检测.
- 现有的复合材料在临床前的AD中缺乏对粉样β (Aβ) 状态的敏感性.
研究的目的:
- 评估一种以数据为导向的认知复合材料方法,以改善在认知无障碍 (CU) 个体中Aβ状态检测.
- 将新型数据驱动复合材料的灵敏度与现有复合材料进行比较.
主要方法:
- 开发了数据驱动的临床前阿尔茨海默氏症认知组合 (D-PACC),使用来自A4研究的Cogstate简要电池 (CBB) 数据的机器学习.
- 在A4研究跟踪和ADNI参与者中,比较D-PACC与传统复合材料的性能.
主要成果:
- D-PACC在区分Aβ状态与现有复合材料方面表现出同等或更好的能力.
- 在A4和ADNI数据集中,D-PACC对Aβ状态表现出一致的敏感性.
结论:
- 在CU群体中,D-PACC为查Aβ+提供了类似或增强的灵敏度.
- D-PACC为识别临床前AD生物标志物的研究提供了更大的一致性.
更多相关视频
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.3K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
